P-L01 Newly detected liver nodules with a history of colorectal cancer: are they metastasis?

2021 ◽  
Vol 108 (Supplement_9) ◽  
Author(s):  
Kai Zhu ◽  
Xiaoying Wang ◽  
Jian Zhou
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Clinicopathological Characteristics ◽  
Gadoxetic Acid ◽  
Accurate Identification ◽  
Liver Nodules ◽  
Enhanced Mri ◽  
Pet Ct ◽  
History Of ◽  
Benign Nodules

Abstract Background The diagnosis of newly detected liver nodules in patients with colorectal cancer (CRC) is crucial for determining prognosis and treatment. Accurate identification of benign nodules can help avoid unnecessary therapy. The aim of our study was to retrospectively review CRC patients who underwent liver resection for newly detected liver nodules in our institution. Methods We went over all patients with a history of CRC, who underwent liver resection from January 2012 to December 2019 in our institution. We specifically focused on nodules pathologically confirmed benign. Clinicopathological characteristics of these patients were collected. Results From 2012 to 2019, a total of 2632 CRC patients received liver resection for liver nodules, among which 2584 cases were proved to be malignant, and 48 cases were benign. Among these 48 cases, 24 were pathologically confirmed as focal nodular hyperplasia (FNH), 10 were inflammatory lesions, 9 were peliosis, and 5 were hemangioma. At least one pre-operative imaging examination (MRI, US, or PET-CT) indicated CRLM, while no one underwent gadoxetic acid-enhanced MRI. The median size of nodule was 2.0 cm (range, 0.4-8.0 cm). For therapy, ten patients received laparoscopic surgery, and 38 patients received open surgery; ten patients received chemotherapy after discovery of liver nodules. Conclusions Newly detected liver nodules with a history of colorectal cancer could be benign. Gadoxetic acid-enhanced MRI should be considered especially for indeterminate liver nodules that would be mimicker of colorectal cancer liver metastasis.

Survival outcomes for patients with equivocal 18FDG-PET CT scan for extrahepatic disease prior to liver resection for metastatic colorectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1581-1581
Author(s):  
Rajiv Kumar ◽  
Carol Beeke ◽  
Shahid Ullah ◽  
Timothy Jay Price ◽  
Rob Padbury ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Resection ◽  
Metastatic Colorectal Cancer ◽  
Ct Scan ◽  
Hazard Ratio ◽  
Extrahepatic Disease ◽  
P Value ◽  
Pet Ct ◽  
Pet Ct Scan ◽  
Tumour Differentiation

1581 Background: Patients considered for liver resection (LR) for hepatic metastases from metastatic colorectal cancer (mCRC) have an 18FDG-PET CT scan (PET) to exclude extrahepatic disease (EHD). The prognostic significance of an equivocal PET on overall survival (OS) for patients who proceed to LR is not entirely clear. The aim of the study is to compare OS for patients with equivocal PET prior to LR to those with a PET negative for EHD. Methods: The South Australian Metastatic Colorectal Cancer Registry collects data for mCRC patients diagnosed after February 1, 2006. Patients were included if they had LR and a PET prior to LR. PETs were coded as no EHD and possible EHD. The Cox proportional hazard model was applied to analyse the outcome of patients with an equivocal PET for EHD on OS, adjusting for possible confounders. Results: Of the 2,480 patients on the registry, 273 had had LR. Of these, 183 (67.0%) had a PET prior to LR, with 137 having no EHD and 46 having possible EHD. The no EHD and possible EHD groups were well balanced for patient, tumour and treatment characteristics – mean age: 66.7 yrs-vs-68.4 yrs, male gender: 61.3%-vs-63.0%, KRAS wildtype: 11.0%-vs-16.3%, stage IV disease at initial diagnosis: 49.6%-vs-54.3%, colonic primary: 74.4%-vs-65.2%, one LR: 82.5%-vs-89.1%, one line of chemotherapy: 52.4%-vs-48.6% and well-moderate tumour differentiation: 85.7%-vs-86.4%. The median follow-up was 32.9 months for no EHD and 33.6 months for possible EHD (P-value = 0.84). The OS for no EHD compared with possible EHD at 1-year was 98.5%-vs-93.5%, at 2-years was 87.6%-vs-88.0%, and at 5-years was 61.5%-vs-59.4%. The unadjusted hazard ratio for OS was 1.22 (95% CI 0.64–2.34, P-value = 0.54) for possible EHD. On adjustment for age, gender, stage at diagnosis, primary site, number of LRs, lines of chemotherapy and tumour differentiation, the hazard ratio remained non-significant; however lower (HR=0.76 (95% CI 0.37–1.59, P-value = 0.47)), for possible EHD. Conclusions: A PET was only performed in 67.0% of patients who had LR for mCRC. There was no difference in OS between patients with no EHD and possible EHD on PET who proceed to LR.

scholarly journals Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with18F-FDG PET/CT

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Ji-Won Oh ◽  
Soon Nam Oh ◽  
Joon Il Choi ◽  
Moon Hyung Choi ◽  
Ie Ryung Yoo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastasis ◽  
Preoperative Evaluation ◽  
Preoperative Staging ◽  
Management Plan ◽  
Clinical Impact ◽  
Gadoxetic Acid ◽  
Liver Mri ◽  
Pet Ct ◽  
Fdg Pet Ct

Objectives. We evaluated the value of Gadoxetic acid-enhanced liver MRI in the preoperative staging of colorectal cancer and estimated the clinical impact of liver MRI in the management plan of liver metastasis.Methods. We identified 108 patients who underwent PET/CT and liver MRI as preoperative evaluation of colorectal cancer, between January 2011 and December 2013. We evaluated the per nodule sensitivity of PET/CT and liver MRI for liver metastasis. Management plan changes were estimated for patients with metastatic nodules newly detected on liver MRI, to assess the clinical impact.Results. We enrolled 131 metastatic nodules (mean size 1.6 cm) in 41 patients (mean age 65 years). The per nodule sensitivities of PET/CT and liver MRI were both 100% for nodules measuring 2 cm or larger but were significantly different for nodules measuring less than 2 cm (59.8% and 95.1%, resp.,P=0.0001). At least one more metastatic nodule was detected on MRI in 16 patients. Among these, 7 patients indicated changes of management plan after performing MRI.Conclusions. Gadoxetic acid-enhanced liver MRI detected more metastatic nodules compared with PET/CT, especially for small (<2 cm) nodules. The newly detected nodules induced management plan change in 43.8% (7/16) of patients.

Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms

2013 ◽  
Vol 40 (2) ◽  
pp. 457-466 ◽  
Author(s):  
Marco Armbruster ◽  
Christoph J. Zech ◽  
Steven Sourbron ◽  
Felix Ceelen ◽  
Christoph J. Auernhammer ◽  
...  
Keyword(s):  
Diagnostic Accuracy ◽  
Liver Metastases ◽  
Gadoxetic Acid ◽  
Neuroendocrine Neoplasms ◽  
Enhanced Mri ◽  
Pet Ct

scholarly journals Aberrant expression of OATP1B3 in colorectal cancer liver metastases and its clinical implication on gadoxetic acid-enhanced MRI

Oncotarget ◽  
2017 ◽  
Vol 8 (41) ◽  
pp. 71012-71023 ◽  
Author(s):  
Seung Hyun Park ◽  
Honsoul Kim ◽  
Eun Kyung Kim ◽  
Hogeun Kim ◽  
Dong Kyu Choi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Clinical Implication ◽  
Gadoxetic Acid ◽  
Colorectal Cancer Liver Metastases ◽  
Aberrant Expression ◽  
Enhanced Mri

scholarly journals The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Daniel Puhr-Westerheide ◽  
Clemens C. Cyran ◽  
Josef Sargsyan-Bergmann ◽  
Andrei Todica ◽  
Franz-Josef Gildehaus ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Diagnostic Value ◽  
Gadoxetic Acid ◽  
Data Sets ◽  
Liver Lesions ◽  
Medullary Thyroid ◽  
Enhanced Mri ◽  
Pet Ct ◽  
Lesion Classification

Abstract Background A high proportion of patients with advanced stages of medullary thyroid carcinoma (MTC) present with liver metastasis metastases. The aim of our study was to investigate the added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in MTC. Methods Thirty-six patients (14 female, median age 55 years) with histologically confirmed MTC undergoing gadoxetic acid-enhanced liver MRI within 1 month of matching contrast-enhanced 18F-DOPA-PET/CT between 2010 and 2016 were selected for this IRB-approved retrospective study. 18F-DOPA-PET/CT and multiparametric MRI data sets were read consecutively and liver lesions were categorised on a 5-point Likert scale (1–definitely benign; 2–probably benign; 3–intermediate risk for metastasis; 4–probably metastasis; 5–definitely metastasis). It was noted if gadoxetic acid-enhanced MRI detected additional, 18F-DOPA-PET/CT-occult metastases (category 5) or if gadoxetic acid-enhanced MRI allowed for a definite classification (categories 1 and 5) of lesions for which 18F-DOPA-PET/CT remained inconclusive (categories 2–4). Follow-up PET/CT and MRI examinations were used as a reference standard. Results A total of 207 liver lesions (18F-DOPA-PET/CT 149, MRI 207; 152 metastases, 37 benign cysts, 18 hemangiomas) were analysed. Fifty-eight additional lesions were detected by MRI, of which 54 were metastases (median diameter 0.5 cm [interquartile range 0.4–0.7 cm]) occult on 18F-DOPA-PET/CT. MRI allowed for a definite lesion classification (categories 1 and 5) in 92% (190/207) whereas 18F-DOPA-PET/CT allowed for a definite lesion classification in 76% (113/149). MRI lead to a change in lesion categorisation in 14% (21/149). Conclusion Gadoxetic acid-enhanced MRI allows for a more precise liver staging in MTC patients compared to 18F-DOPA-PET/CT alone, particularly for 18F-DOPA-negative metastases and lesions < 1 cm.

Prognostic value of LI-RADS category on gadoxetic acid–enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas

2020 ◽  
Author(s):  
Ji Hye Min ◽  
Seong Hyun Kim ◽  
Jeong Ah Hwang ◽  
Seung Hyup Hyun ◽  
Sang Yun Ha ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Prognostic Value ◽  
Gadoxetic Acid ◽  
Enhanced Mri ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document